`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`MYLAN PHARMACEUTICALS INC.
`Petitioner
`
`v.
`
`QUALICAPS CO. LTD.
`Patent Owner
`
`U.S. Patent No. 6,649,180
`Filing Date: April 13, 2000
`Issue Date: November 18, 2003
`Title: HARD CAPSULE FORMED OF CELLULOSE ETHER FILM WITH A
`SPECIFIC CONTENT OF METHOXYL AND HYDROXYPROPOXYL
`GROUPS
`________________
`
`Inter Partes Review No. 2017-00203
`
`
`
`DECLARATION OF MR. JONATHAN D. OLINGER IN SUPPORT OF
`PETITIONER’S UNOPPOSED MOTION FOR PRO HAC VICE
`ADMISSION UNDER 37 C.F.R. § 42.10(c)
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 1
`
`
`
`
`
`
`
`I, Jonathan D. Olinger, am over eighteen years of age and would be
`
`competent to testify as to the matters set forth herein if called upon to do so.
`
`1. I am a member in good standing of the state bar of Georgia, as well
`
`as the following Federal Courts:
`
`a. U.S. District Court for the Northern District of Georgia;
`
`b. U.S. District Court for the Eastern District of Texas; and
`
`c. U.S. District Court for the District of Colorado.
`
`I have never been suspended or disbarred from practice before any
`
`court or administrative body.
`
`I have never had an application for admission to practice before any
`
`court or administrative body denied.
`
`No sanction or contempt citation has been imposed against me by any
`
`court or administrative body.
`
`During the past 3 years, I have applied to appear pro hac vice before
`
`the United States Patent and Trademark Office in the following
`
`proceedings:
`
`a. Under Armour, Inc. v. Adidas AG, Case IPR2015-00697;
`
`b. Under Armour, Inc. v. Adidas AG, Case IPR2015-00698;
`
`c. Under Armour, Inc. v. Adidas AG, Case IPR2015-00700;
`
`d. Under Armour, Inc. v. Adidas AG, Case IPR2015-01528; and
`
`- 1 -
`
`2.
`
`3.
`
`4.
`
`5.
`
`
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 2
`
`
`
`
`
`6.
`
`
`
`e. Under Armour, Inc. v. Adidas AG, Case IPR2015-01532.
`
`I have read and will comply with the Office Patent Trial Practice
`
`Guide and the Board’s Rules of Practice for Trials set forth in part 42
`
`of 37 C.F.R.
`
`7.
`
`I will be subjected to the USPTO Rules of Professional Conduct set
`
`forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under
`
`37 C.F.R. § 11.19(a).
`
`8. I am familiar with the subject matter at issue in the proceeding. I am
`
`counsel for Mylan Pharmaceuticals, Inc. in a co-pending litigation,
`
`Warner Chilcott (US), LLC et al. v. Mylan Pharmaceuticals, Inc., et
`
`al., Case No. 2:15-cv-01740-JRG-RSP (E.D. Texas) in which U.S.
`
`Patent No. 6,649,180 is asserted against Petitioner. In the co-pending
`
`litigation, I have reviewed prior art, developed validity arguments,
`
`developed claim construction arguments, managed fact and expert
`
`discovery, and drafted motion papers. I therefore have an established
`
`familiarity with the subject matter at issue in the proceeding,
`
`including the prior art relied upon in the Petition.
`
`9.
`
`I have been a litigating attorney in private practice since 2010, with
`
`trial experience in numerous litigations involving patent infringement
`
`
`
`- 2 -
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 3
`
`
`
`and validity in federal eourts across the country, including experience
`
`injury and bench trials and appeals in the Federal Circuit.
`
`10.
`
`An abbreviated summary of my professional biography is Attachment
`
`A to this Declaration.
`
`Date: December 21,2016
`
`Jonathan D. Olinger
`Kjjf^trick, Townsend & Stockton LLP
`1100 Peachtree Street NE, Suite 2800
`Atlanta, GA 30309-4528
`
`12172643V. 1
`
`-3 -
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 4
`
`
`
`
`
`EXHIBIT A
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 5
`
`
`
`11/29/2016
`
`{1
`
`KILPATRICK
`
`TOWNSEND
`
`Kilpatrick Townsend & Stockton LLP - Olinger, Jonathan D.
`
`
`
`Jonathan D. Olinger
`ASSOCIATE
`
`Services
`
`Intellectual Property; Patent Litigation; Intellectual Property Litigation
`
`Industries
`
`Aerospace & Defense; Pharmaceuticals; Technology & Software; Telecommunications
`
`Jonathan Olinger focuses his practice on patent litigation matters. His practice covers a range of technologies, including
`
`pharmaceuticals, software-related systems, and telecommunications. Mr. Olinger has experience in all phases of patent
`
`litigation, including fact and expert discovery, depositions, claim construction, motion practice and trial.
`
`Prior to joining the firm, Mr. Olinger worked as an associate in the Atlanta office of a national law firm. Before entering private
`
`practice, Mr. Olinger was a law clerk for the Honorable Timothy C. Batten, Sr., United States District Judge for the Northern
`District of Georgia.
`
`Professional & Community Activities
`Georgia Bar Association, Intellectual Property Section, Committee Chair (2012-Present)
`
`Atlanta Intellectual Property Inn of Court, Member
`
`Institute for Responsible Citizenship, Board of Trustees, Member (2008-Present)
`
`Education
`
`- Stanford Law School, J.D. (2008)
`
`- Georgia Institute of Technology, B.S., Aerospace Engineering, Minors in Law, Science and Technology (2005)
`with highest honors
`
`Bar Admissions
`
`- Georgia (2009)
`
`Admissions
`
`- U.S. District Court for the Northern District of Georgia (2010)
`
`- Georgia Superior Court (2009)
`
`Clerkships
`
`- U.S. District Court for the Northern District of Georgia — Honorable Timothy C. Batten, Sr. (Aug 2008-Aug 2010)
`
`Suite 2800, 1100 Peachtree Street NE
`
`_
`_
`_
`_
`_
`Atlanta, GA, 30309-4528
`, Petitioner M Ian Pharmaceuticals Inc. - Exhibit 1015 - Page 6
`.
`,
`http://www.kiIpatricktownsend.com/en/Who_We_Are/Professionals/O/OIingerJon hanD16245.aspx
`
`1/2
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 6
`
`
`
`11/29/2016
`
`USA
`
`t +1 404.745.2426.
`
`f+1 404.541.3326
`
`e-mailvcardprint full bio
`
`Kilpatrick Townsend & Stockton LLP - Olinger, Jonathan D.
`
`Jonathan D. Olinger
`
`Experience Highlights
`
`Shire LLC v. Watson Pharmaceuticals, Inc.
`
`Represented Watson Pharmaceuticals, Inc.
`treat ADHD. more
`
`in patent litigation relating to generic forms of guanfacine hydrochloride used to
`
`Intellectual Ventures v. Motorola Mobility LLC
`
`The firm served as lead counsel on behalf of Motorola Mobility, in a lawsuit involving allegations of patent infringement related
`to mobile phone more
`
`Monec Holding AG v. Motorola Mobility, Inc.
`
`The firm served as lead counsel for Motorola Mobility in a patent infringement suit filed by Monec in the District of Delaware.
`The parties more
`
`Inter partes review challenge for C&D Zodiac
`
`Kilpatrick Townsend successfully instituted an inter partes review of U.S. Patent No. 8,590,838, titled “Aircraft Interior more
`
`, Petitioner M Ian Pharmaceuticals Inc. - Exhibit 1015 - Page 7
`.
`.
`http://www.kiIpatncktownsend.com/en/Who_We_Are/ProfessIonals/O/OIIngerJon hanD16245.aspx
`
`2/2
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1015 - Page 7
`
`